CVE-2012-1710
Published: May 25, 2022
Official Description
Unspecified vulnerability in the Oracle WebCenter Forms Recognition component in Oracle Fusion Middleware allows remote attackers to affect confidentiality, integrity, and availability via Unknown vectors related to Designer.
CISA KEV Advisory
Oracle Fusion Middleware Unspecified Vulnerability
Unspecified vulnerability in the Oracle WebCenter Forms Recognition component in Oracle Fusion Middleware allows remote attackers to affect confidentiality, integrity, and availability via Unknown vectors related to Designer.
Apply updates per vendor instructions.
Risk Analysis
An unspecified vulnerability in Oracle WebCenter Forms Recognition component of Oracle Fusion Middleware allows remote attackers to impact confidentiality, integrity, and availability. The high EPSS score of 0.60110 and confirmed exploitation indicate this is a critical vulnerability.
This vulnerability is actively exploited in the wild and is included in CISA's KEV catalog. The exploitation vectors are unknown but are remote.
Apply the latest security updates or patches for Oracle WebCenter Forms Recognition and Oracle Fusion Middleware. Restrict network access to the affected component.
Technical Analysis
CVE-2012-1710 requires local access, meaning attackers must already have a foothold on the target system.
Exploitation requires some privileges, which limits the exposure to scenarios where an attacker has already gained initial access.
CISA has added CVE-2012-1710 to the Known Exploited Vulnerabilities (KEV) catalog, confirming active exploitation in the wild. U.S. federal agencies are required to patch this within the mandated timeframe, and all organizations should treat remediation as urgent.
Affected Vendors & Products
Exploit & PoC Resources
All References (1)
Quick Facts
Recommended Actions
- →Apply vendor patches immediately
- →Monitor CVE-2012-1710 in threat intel feeds
- →Review IDS/IPS signatures for exploitation attempts
- !CISA KEV: Federal agencies must patch per BOD 22-01 timeline
- !Active exploitation confirmed — treat as P1